Wealth Group’s Gilead Sciences GILD Stock Holding History

Wealth Group’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-2,953	Closed	-$331K	–	119
2025 Q1	$331K	Sell	2,953 -261	-8%	-$26.9K	0.21%	98
2024 Q4	$297K	Buy	+3,214	New	+$289K	0.19%	119
2024 Q2	–	Sell	-2,939	Closed	-$215K	–	150
2024 Q1	$215K	Buy	+2,939	New	+$226K	0.16%	138

Other funds holding GILD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Wealth Group's GILD Position: Q2 2025 in Review

Wealth Group sold out of Gilead Sciences (GILD) in Q2 2025, closing a stake of 2,953 shares — an estimated $331K sold.

Wealth Group first reported a position in GILD in Q1 2024 and held it in 3 quarters. The position peaked at $331K in Q1 2025. 2,023 funds tracked by Wall St. Rank hold GILD as of Q2 2025.

Wealth Group reported no remaining Gilead Sciences position as of Q2 2025 after selling out during the quarter.
Wealth Group sold 2,953 Gilead Sciences shares in Q2 2025, an estimated $331K.
Wealth Group first reported a position in Gilead Sciences in Q1 2024 and held it in 3 quarters.
Wealth Group's Gilead Sciences position peaked at $331K in Q1 2025.
2,023 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2025.

Based on Wealth Group's 13F filing for Q2 2025, filed 19 Aug 2025.